Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approachHsiao-Tzu Chien, Peter van Meer, Maggie Dempster et al.|Regulatory Toxicology and Pharmacology|2022Cited by 32
Survey results on the use of the tissue cross-reactivity immunohistochemistry assayJeanine L. Bussiere, Ruth Lightfoot-Dunn, Michael W. Leach et al.|Regulatory Toxicology and Pharmacology|2010Cited by 24
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainHelen Prior, Lucinda Weir, Laura Andrews et al.|Regulatory Toxicology and Pharmacology|2023Cited by 15
Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe surveyDavid O. Clarke, Thierry Flandre, Kaushik Datta et al.|Regulatory Toxicology and Pharmacology|2024Cited by 4
LP-18: Challenges and Opportunities in Use of the Minipig for Nonclinical Pharmaceutical Development: Results of the Second IQ DruSafe Minipig SurveyJoanna Harding, Béatrice Gauthier, Kaushik Datta et al.|Toxicology Letters|2023Cited by 0